What is the recommended duloxetine dosing for depression in adults, including starting dose, titration, maximum dose, and adjustments for patients over 65, hepatic impairment, or renal impairment?

Duloxetine Dosing for Depression in Adults

Start duloxetine at 30 mg once daily for 1 week, then increase to the target therapeutic dose of 60 mg once daily; this approach significantly reduces treatment-emergent nausea while producing only a transient delay in therapeutic effect compared to starting at 60 mg daily. 1, 2, 3

---

Standard Adult Dosing (Under 65 Years)

Initial Dosing

• Starting dose: 30 mg once daily for 1 week 1, 2, 3
• Target maintenance dose: 60 mg once daily 1, 2
• Alternative FDA-approved starting regimen: 40 mg/day (20 mg twice daily) to 60 mg/day (either once daily or 30 mg twice daily), though the 30 mg × 1 week approach is better tolerated 2

Dose Escalation

• Maximum dose: 120 mg/day (administered as 60 mg twice daily) 1, 2
• Evidence for higher doses: While 120 mg/day has been shown effective, there is no evidence that doses greater than 60 mg/day confer additional benefits for depression 1, 2
• Escalation schedule: If increasing beyond 60 mg/day, use 30 mg increments with at least 1–2 weeks at each dose level to assess response 1

Rationale for 30 mg Start

• Starting at 30 mg for 1 week reduces nausea incidence from 32.9% (60 mg start) to 16.4% (30 mg start) during the first week 3
• This lower starting dose produces only a transitory 1-week delay in therapeutic effect on core depressive symptoms, with no significant differences in efficacy after week 2 3
• Discontinuation rates due to adverse events over 12 weeks are lower with the 30 mg start (13.4% vs 18.6% for 60 mg start, though not statistically significant) 3

---

Dosing in Patients ≥65 Years

Geriatric-Specific Recommendations

• Starting dose: 30 mg once daily for at least 2 weeks (longer than younger adults) 1, 2
• Target dose: 60 mg/day after the initial 2-week period 1, 2
• Escalation: If increasing beyond 60 mg/day, use 30 mg increments with a minimum of 1 week at each dose level 1
• Maximum studied dose: 120 mg/day 1

Safety Considerations in Elderly

• Older adults are more prone to severe adverse effects including cognitive impairment, falls, and drug-drug interactions related to polypharmacy 1
• A slower titration strategy (30 mg increments with ≥1 week intervals) enhances tolerability and safety across all indications 1
• Duloxetine is generally safe and well tolerated in elderly patients with depression, with discontinuation rates due to adverse events similar to placebo (9.7% vs 8.7%) 4

---

Dosing Adjustments for Hepatic Impairment

• Severe hepatic impairment: Duloxetine is contraindicated 1
• Mild-to-moderate hepatic impairment: Dose reduction is required, though specific dose recommendations are not provided in the FDA label; start at the lowest dose (30 mg/day) and titrate cautiously 1, 2

---

Dosing Adjustments for Renal Impairment

Mild-to-Moderate Renal Impairment (CrCl ≥30 mL/min)

• No dose adjustment necessary 5
• Population pharmacokinetic analyses show that mild or moderate renal impairment does not significantly affect duloxetine clearance 5

Severe Renal Impairment or End-Stage Renal Disease (CrCl <30 mL/min)

• Duloxetine is not recommended 1, 5
• In patients with end-stage renal disease, duloxetine exposure (AUC and Cmax) is approximately 2-fold higher than in healthy subjects 5
• Inactive conjugated metabolites accumulate 2- to 9-fold, reflecting reduced renal clearance 5
• Clinical recommendation: Consider a lower starting dose (30 mg/day) and gradual titration if duloxetine must be used, though avoidance is preferred 1, 2

---

Monitoring and Safety

Common Adverse Effects

• Nausea (16–38%, dose-dependent, most prominent in first week) 1
• Dry mouth, constipation, diarrhea, headache, dizziness, fatigue, decreased appetite, somnolence 1
• Management: Taking duloxetine with food can reduce nausea 6

Cardiovascular Monitoring

• Monitor blood pressure and heart rate at baseline and with each dose increase, as duloxetine can cause modest increases in systolic/diastolic BP and heart rate 1, 4
• In elderly patients, changes in supine/standing BP and pulse were not significantly different from placebo, except for a small decrease in orthostatic systolic BP (−2.45 vs +0.93 mm Hg) 4

Treatment Response Assessment

• Assess response at 4 weeks and 8 weeks using standardized depression scales (e.g., PHQ-9, HAMD-17) 1
• Most patients achieve adequate response by 4–6 weeks at 60 mg daily 1
• If no response after 4–8 weeks at 120 mg daily, consider switching to a different medication class rather than further dose increases 1

---

Discontinuation Protocol

• Taper gradually over at least 2–4 weeks when discontinuing after more than 3 weeks of treatment 1
• Abrupt discontinuation can cause withdrawal syndrome (dizziness, fatigue, nausea, headache, irritability, anxiety, sensory disturbances, paresthesias) 1
• For patients with a history of withdrawal symptoms, consider a slower taper over 3–4 weeks with smaller dose decrements (e.g., 120 mg → 100 mg → 80 mg → 60 mg → 30 mg → discontinue) 1

---

Key Clinical Pitfalls to Avoid

1. Do not start at 60 mg in patients concerned about tolerability—the 30 mg × 1 week approach significantly reduces nausea without compromising long-term efficacy 3

2. Do not exceed 120 mg/day—higher doses provide no additional benefit and increase adverse effects 1, 2

3. Do not use in severe renal impairment (CrCl <30 mL/min)—duloxetine and metabolite exposure increases significantly 5

4. Do not use in severe hepatic impairment—absolute contraindication 1

5. Do not discontinue abruptly—always taper over 2–4 weeks to prevent withdrawal syndrome 1

6. Monitor for suicidal thoughts in young adults (18–24 years) during the first few months of treatment, though duloxetine is protective in adults ≥65 years 1, 6